The University of Texas MD Anderson Cancer Center today announced it has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDe switch platform and the GoCAR platform.
MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals
- Post author:
- Post published:February 22, 2024
- Post category:uncategorized